Search clinical trials for: Plerixafor

Total 169 results

M.D. Anderson Cancer Center
Pfizer

Not yet recruiting

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Multiple Myeloma | Post-transplant MRD-guided Maintenance Therapy | Pre-transplant Purging

United States
Washington University School of Medicine
The Leukemia and Lymphoma Society; Rising Tide Foundation; St. Louis Children...

Not yet recruiting

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML (ABCD-NK)

Acute Myeloid Leukemia | Aml | AML, Childhood | Acute Myeloid Leukemia, Pediatric

United States
Gruppo Oncologico del Nord-Ovest

Recruiting

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Colorectal Cancer | Resectable Colorectal Carcinoma

Italy
West German Study Group
AstraZeneca

Not yet recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)

HER2-positive Early Breast Cancer

Germany
Peking University

Recruiting

Plerixafor for Poorly Mobilized Lymphoma

Lymphoma

China
Shandong University
Tianjin Central Hospital of Gynecology Obstetrics

Recruiting

Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in Neonates

Infectious Disease

China
Women's Hospital School Of Medicine Zhejiang University
Jinhua Central Hospital; The Children's Hospital of Zhejiang University School... and other collaborators

Not yet recruiting

Intelligent Follow-up of Neonatal Jaundice Based on Early Indicators and Internet Communications

Hyperbilirubinemia, Neonatal
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Sickle Cell Anemia | Beta Thalassemia

United States
Hugh Taylor

Recruiting

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Asherman Syndrome | Recurrent Implantation Failure | Atrophic Endometrium

United States
Stanford University
Orca Biosystems, Inc.

Recruiting

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute Leukemia | Chronic Myelogenous Leukemia | Allogeneic Hematopoietic Cell Transplantation (HCT) | Advanced Hematologic Malignancies

United States
Centre Hospitalier Universitaire, Amiens
University Hospital, Rouen

Recruiting

Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid (DERMOS)

Osteoporosis | Bullous Pemphigoid

France
Lawrence D Recht
Sanofi

Recruiting

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Glioblastoma | Malignant Glioma | Gliosarcoma | Glioblastoma With Primitive Neuronal Component | Oligodendroglial Component Present

United States
City of Hope Medical Center

Recruiting

Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO)

Sickle Cell Disease

United States
IRCCS San Raffaele
Fondazione Telethon

Recruiting

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD (XCGD-MOBI)

Chronic Granulomatous Disease X-linked (X-CGD)

Italy
National Institute of Allergy and Infectious Diseases...

Recruiting

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Idiopathic CD4-Positive | T-Lymphocytopenia

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

Infections | Warts | Neutropenia | Leukopenia | Myelokathexis

United States
National Institute of Allergy and Infectious Diseases...

Enrolling by invitation

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Chronic Granulomatous Disease (CGD) | X-Linked Chronic Granulomatous Disease

United States
Hospital Infantil Universitario Niño Jesús, Madrid...
Universitat Autonoma de Barcelona; Instituto de Investigación Sanitaria de... and other collaborators

Completed

Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A (FANCOLEN-1)

Fanconi Anemia

Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Genzyme, a Sanofi Company; American Association...

Completed

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Fondazione EMN Italy Onlus

Completed

Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients

Multiple Myeloma

Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Suspended

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV

HIV | Hematologic Malignancies

United States
University of Chicago

Active, not recruiting

Stem Cell Transplantation for Patients With Multiple Myeloma

Myeloma

United States
Ensoma

Completed

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

Healthy Volunteers

United States
Ensoma
bluebird bio

Terminated

Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Sickle Cell Disease

United States
Ensoma
National Marrow Donor Program

Terminated

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Healthy Donors | Related Donors Donating PBSC to a Family Member

United States
The First Hospital of Jilin University

Active, not recruiting

Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Relapsed Adult AML | Relapsed Adult ALL

China
Sangamo Therapeutics

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Sickle Cell Disease

United States
Memorial Sloan Kettering Cancer Center
Sanofi; Duke University; Weill Medical College of Cornell University; New York...

Active, not recruiting

Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

Sickle Cell Disease

United States
Jonsson Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)

Terminated

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Sarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive

United States
National Heart, Lung, and Blood Institute (NHLBI)
St. Jude Children's Research Hospital

Completed

Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients

Sickle Cell Disease

United States
Center for International Blood and Marrow Transplant...
Sanofi; Genzyme, a Sanofi Company

Completed

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Hodgkin's Disease | Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member

United States
St. Jude Children's Research Hospital

Suspended

Reduced Intensity Transplantation for Severe Sickle Cell Disease

Sickle Cell Disease

United States
Aalborg University

Enrolling by invitation

Testing Protocol to Efficiently Induce Itch (ELIT)

Itch

Denmark
University of Alberta
Alberta Innovates Health Solutions

Active, not recruiting

Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

Diabetes Mellitus, Type 1

Canada
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI); Rocket Pharma Limited

Active, not recruiting

Gene Therapy for Fanconi Anemia

Fanconi Anemia

United States
Memorial Sloan Kettering Cancer Center
Sanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaborators

Active, not recruiting

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Scleroderma Treatment With Autologous Transplant (STAT) Study (STAT)

Systemic Scleroderma

United States
4Living Biotech

Withdrawn

Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb) (LEONARDO)

COVID-19 | COVID-19 Acute Respiratory Distress Syndrome

France, Bulgaria
St. Jude Children's Research Hospital
Doris Duke Charitable Foundation

Withdrawn

Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor

Sickle Cell Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

Infections | Warts | Neutropenia | Myelokathexis | Hypogammaglobulinemia

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Multiple Myeloma and Malignant Lymphoma

Japan
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center

Terminated

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

T-cell Non-Hodgkin Lymphoma

United States
Sanofi

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Autologous Haematopoietic Stem Cell Transplant

China
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Withdrawn

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

Osteosarcoma | Bone Metastases

United States
Surbhi Sidana, MD

Completed

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Multiple Myeloma

United States
Fred Hutchinson Cancer Center

Terminated

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Glioblastoma | Gliosarcoma

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers

Normal Physiology

United States
Assistance Publique - Hôpitaux de Paris
EuroFancolen

Completed

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor (FancoMob)

Fanconi Anemia

France
National Heart, Lung, and Blood Institute (NHLBI)

Completed

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

Healthy

United States

Search clinical trials for: Plerixafor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations